In primary cells, despite considerable heterogeneity, SREBP and FASN inhibitors can still decrease overall cellular proliferation, especially in malignant cells compared to non-malignant cells, suggesting a great therapeutic potential of FASN and SREBP in the CTCL. The gene discussed is FASN; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.